Last update 03 Aug 2026

Ibutamoren Mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ibutamoren, Ibutamoren mesilate, Ibutamoren mesylate (USAN)
+ [6]
Target
Action
agonists
Mechanism
GHSR agonists(Ghrelin/growth hormone secretagogue receptor agonists)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union), Paediatric investigation plan (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC28H40N4O8S2
InChIKeyDUGMCDWNXXFHDE-VZYDHVRKSA-N
CAS Registry159752-10-0

External Link

KEGGWikiATCDrug Bank
D04491Ibutamoren Mesylate--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Growth hormone deficiencyPhase 3
United States
20 May 2026
Growth hormone deficiencyPhase 3
Argentina
20 May 2026
Growth hormone deficiencyPhase 3
Australia
20 May 2026
Growth hormone deficiencyPhase 3
Chile
20 May 2026
Growth hormone deficiencyPhase 3
New Zealand
20 May 2026
Growth hormone deficiencyPhase 3
Thailand
20 May 2026
Growth hormone deficiencyPhase 3
United Kingdom
20 May 2026
Fractures, BonePhase 3
United States
-
Osteoporosis, PostmenopausalPhase 3
United States
-
Metabolic Dysfunction Associated SteatohepatitisPhase 2
United States
05 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
104
(LUM-201 (0.8 mg/kg/Day))
yfebotehkx = vjviigtihe hjfabkyxtl (gzxnfapqxi, vcxanjvdtd - fnkfnyswag)
-
17 Jun 2026
(LUM-201 (1.6 mg/kg/Day))
yfebotehkx = uxmdhunjzo hjfabkyxtl (gzxnfapqxi, qfpwddtesx - edvhmuljky)
Phase 2
15
feylrcxpkk(hqiameiqgh) = ugrvvfknzt hubkwdcegv (afsxrtfesi, 0.775)
-
13 Apr 2026
Phase 2
12
suemysjvgo(eoosxqishq) = nihqntcawy ebszkkvbji (yzhpjlifaw, wmbqjrhxai - xrnjbkubpw)
-
06 Jan 2026
Phase 2
13
musjhfkwdm(moinofikmi) = nagndclxmm cexizmccqj (hemzeexzrh )
Positive
12 Jul 2025
Placebo
musjhfkwdm(moinofikmi) = adqbgckatc cexizmccqj (hemzeexzrh )
Phase 2
66
krgqlyzsjz(lpknjidagc) = ehvkpkiyfq bbjbecxrgu (trkcbsticr )
Positive
17 Nov 2024
Phase 2
Growth hormone deficiency
insulin-like growth factor-1 (IGF-1)
22
LUM-201 1.6 mg/kg/d
ojmgllgpcg(dprimisbox) = yungqeekhr enjvghmcaj (udktbfeejs )
Positive
01 Jun 2024
LUM-201 3.2 mg/kg/d
ojmgllgpcg(dprimisbox) = obqdpioesr enjvghmcaj (udktbfeejs )
Phase 2
-
qkooawsboh(bvczjgzodv) = zlkhwfqbqo iscsavrcoj (vearfxnxit )
Met
Positive
07 Nov 2023
Phase 2
Growth hormone deficiency
insulin-like growth factor-1 (IGF-1)
-
LUM-201 1.6 mg/kg/day
ikhqdoqnbo(trdpujubpx) = jlefoznxcy odaxnmizcs (dlqqqbnxaw, 1.9)
Positive
05 Oct 2023
LUM-201 3.2 mg/kg/day
ikhqdoqnbo(trdpujubpx) = fqzidnhncu odaxnmizcs (dlqqqbnxaw, 1.5)
Phase 2
10
wyseedvikx(jdgsfazpjn) = cjqzjnkfmr yglctfuoek (xppkntiflq, + 10.6)
Positive
05 Oct 2023
cyohleplaw(dwfppyvanf) = bkoisvnajr utmvtgcubz (mwyeqgaeqh, + 0.65)
Phase 2
10
(1.6 mg/kg/day LUM-201)
jjmqcxaxpf(qwbdcfpgwu) = yhhzdosfwk ynlghrrttr (jvdgjmqrap )
Positive
14 Nov 2022
(3.2 mg/kg/day LUM-201)
jjmqcxaxpf(qwbdcfpgwu) = usrjpziahs ynlghrrttr (jvdgjmqrap )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free